Morgans Sticks to Its Buy Rating for Amcor PLC Shs Chess Depository Interests (AMC)
Morgans analyst Alexander Lu maintained a Buy rating on Amcor PLC Shs Chess Depository Interests (AMC – Research Report) today and set a price target of A$16.00. The company's shares closed today at A$14.07.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Lu covers the Industrials sector, focusing on stocks such as Reliance Worldwide Corp., Brambles , and Acrow Formwork and Construction Services Limited. According to TipRanks, Lu has an average return of 5.2% and a 40.51% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amcor PLC Shs Chess Depository Interests with a A$17.60 average price target.
The company has a one-year high of A$16.96 and a one-year low of A$13.82. Currently, Amcor PLC Shs Chess Depository Interests has an average volume of 2.86M.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
39 minutes ago
- Business Insider
CF Industries to host investor day
Investor Day to be held on June 24 at 9:30 am. Webcast Link Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Business Insider
an hour ago
- Business Insider
Carnival Stock (CCL) Dips on Loyalty Program Changes
Carnival (CCL) stock slipped on Monday after the cruise line company announced controversial changes to its loyalty program. The company will nix its Very Important Fun Person (VIFP) program next year in favor of a new rewards program. This issue with this is that it will change how passengers earn rewards. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The new program will allow customers to earn benefits over two years, and retain those benefits for another two. For comparison, the current loyalty program offered benefits for life. Another change is how points are earned: the new system offers points for money spent, while the current one gives points based on nights booked. These changes are designed to limit the number of guests who have access to the highest level of rewards. The decision to switch to this system was made after the current loyalty program become inflated with members who have benefits for life. While the new system alleviates this issue, it isn't going over well with loyalty members. Carnival Stock Ratings and Movement Today James Hardiman. This suggests a possible 19.91% upside for CCL stock. CCL shares were down 1.72% on Monday following the new loyalty program reveal. Investors will note the stock is also down 6.4% year-to-date but has rallied 45.03% over the past 12 months. Is CCL Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Carnival is Moderate Buy, based on 13 Buy and five Hold ratings over the past three months. With that comes an average CCL stock price target of $28.73, representing a potential 23.04% upside for the shares.
Business Insider
2 hours ago
- Business Insider
Why Is Impact BioMedical Stock (IBO) Up 200% Today?
Impact BioMedical (IBO) stock skyrocketed on Monday after the specialty biopharmaceutical and consumer healthcare company announced a merger agreement with Hong Kong-based pharmaceutical company Dr Ashleys Limited. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter These two companies have agreed to a reverse merger that will see Dr Ashleys Limited acquire Impact BioMedical, with the combined company trading under the Dr Ashleys Limited name. The Dr Ashleys management team will lead the combined company and will also create a new Board of Directors. Dr. Kanans Visvanats, director of Dr. Ashleys Limited, said, 'By integrating Impact Biomedical's impressive IP portfolio into our R&D efforts, we are poised to accelerate the development of groundbreaking therapies and expand our Impact on global health.' IBO Stock Movement Today
